Characteristic | sHLA-G (mean ± SD); ng/ml | p (pc) | |
---|---|---|---|
UC (N = 30) | CD (N = 30) | ||
Gender | |||
Male | 192.0 ± 24.1 | 173.5 ± 25.1 | 0.005 (0.050) |
Female | 170.5 ± 26.2 | 164.9 ± 27.5 | 0.542 (NS) |
p (pc) | 0.003 (0.030) | 0.292 (NS) | |
Cigarette smoking status | |||
Smoker | 187.9 ± 24.2 | 162.8 ± 25.9 | 0.004 (0.040) |
Non-smoker | 165.9 ± 27.9 | 175.0 ± 26.2 | 0.419 (NS) |
p (pc) | 0.033 (NS) | 0.181(NS) | |
Disease duration (years) | |||
≤ 3 | 175.1 ± 32.2 | 164.9 ± 24.0 | 0.362 (NS) |
> 3 | 184.1 ± 23.4 | 172.9 ± 28.7 | 0.233 (NS) |
0.376 (NS) | 0.417 (NS) | ||
Family history | |||
Yes | 193.3 ± 31.7 | 174.7 ± 23.4 | 0.332 (NS) |
No | 178.6 ± 26.5 | 167.8 ± 27.2 | 0.152 (NS) |
p (pc) | 0.352 (NS) | 0.647 (NS) | |
Disease extension | |||
Ulcerative proctitis | 185.4 ± 32.3 | ||
Left-sided colitis | 170.2 ± 19.3 | ||
Extensive colitis | 182.6 ± 25.0 | ||
Ileocecal | 171.6 ± 25.2 | ||
Ileo-colonic | 155.3 ± 30.5 | ||
p (pc) | 0.457 (NS) | 0.212 (NS) | |
Abdominal/or colon pain | |||
Present | 184.7 ± 29.9 | 165.1 ± 23.6 | 0.030 (NS) |
Absent | 169.1 ± 12.5 | 174.0 ± 29.7 | 0.662 (NS) |
p (pc) | 0.558 (NS) | 0.841 (NS) | |
Diarrhea | |||
Present | 184.6 ± 23.1 | 165.0 ± 27.6 | 0.032 (NS) |
Absent | 172.3 ± 33.6 | 171.9 ± 25.8 | 1.000 (NS) |
p (pc) | 0.224 (NS) | 0.485 (NS) | |
Fever | |||
Present | 192.3 ± 27.0 | 169.4 ± 28.7 | 0.051 (NS) |
Absent | 171.6 ± 24.2 | 168.6 ± 25.5 | 0.725 (NS) |
p (pc) | 0.040 (NS) | 1.000 (NS) | |
Medication | |||
Protocol A | 191.9 ± 23.6 | 167.6 ± 32.7 | 0.085 (NS) |
Protocol B | 189.7 ± 26.3 | 159.8 ± 10.3 | 0.079 (NS) |
Protocol C | 167.5 ± 15.3 | 181.8 ± 19.2 | 0.199 (NS) |
Protocol D | 170.8 ± 32.0 | 165.2 ± 29.4 | 0.741 (NS) |
p (pc) | 0.119 (NS) | 0.184 (NS) | |
Adalimumab or infliximab doses | |||
0 | 189.7 ± 26.3 | 159.8 ± 10.3 | 0.079 (NS) |
1–10 | 185.6 ± 23.7 | 172.8 ± 28.1 | 0.229 (NS) |
11–20 | 176.6 ± 24.6 | 161.2 ± 26.8 | 0.193 (NS) |
21–30 | 156.5 ± 47.5 | 197.8 ± 11.5 | 0.217 (NS) |
p (pc) | 0.334 (NS) | 0.144 (NS) |